Skip to content

Study · Systematic review · n = 575 · 2026

9 results

Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.

Dong J, Liu M, Liu Z

Pediatric research3 Nov 2025

PMID41184626 (opens in a new tab)DOI10.1038/s41390-025-04537-5 (opens in a new tab)PepBankPUB-41184626
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased body mass index versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered body mass index more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.57
    body mass index

    Source sentences

    Summary
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    3 context sentences
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased body mass index z-score versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered body mass index z-score more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index z-score
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.45
    body mass index z-score

    Source sentences

    Summary
    BMI z-score (WMD: -0.45; P < 0.00001)
    4 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  3. 03HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased body weight versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.31
    body weight

    Source sentences

    Summary
    body weight (WMD: -0.31; P = 0.0004)
    4 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  4. 04HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased HbA1c versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.43
    HbA1c

    Source sentences

    Summary
    HbA1c (WMD: -0.43; P = 0.004)
    4 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  5. 05HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased fasting plasma glucose versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered fasting glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −1.23
    fasting plasma glucose

    Source sentences

    Summary
    fasting plasma glucose (WMD: -1.23; P = 0.003)
    4 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  6. 06HumanSystematic reviewEfficacy outcome

    In children and adolescents with obesity, liraglutide decreased systolic blood pressure versus placebo.

    In plain wordsIn children and adolescents with obesity, liraglutide lowered systolic blood pressure more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 575

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.2
    systolic blood pressure

    Source sentences

    Summary
    systolic blood pressure (WMD: -0.20; P = 0.03)
    4 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
    Summary · context
    Seven trials involving 575 patients were included in the analysis.
  7. 07HumanSystematic reviewEfficacy outcome

    Among liraglutide-treated pediatric patients, body mass index z-score did not differ significantly between children aged 6-12 years and adolescents.

    In plain wordsWith liraglutide, body mass index z-score did not differ significantly between children aged 6-12 and adolescents with obesity.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody mass index z-score in children aged 6-12 years
    Study

    n: not reported in source

    Comparator
    Adolescents
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroup analyses found that children 6-12 years of age did not have a significantly different BMI z-score (z = 1.76; P = 0.08) and body weight (z = 1.75; P = 0.08) versus adolescents.
    3 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
  8. 08HumanSystematic reviewEfficacy outcome

    Among liraglutide-treated pediatric patients, body weight did not differ significantly between children aged 6-12 years and adolescents.

    In plain wordsWith liraglutide, body weight did not differ significantly between children aged 6-12 and adolescents with obesity.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight in children aged 6-12 years
    Study

    n: not reported in source

    Comparator
    Adolescents
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroup analyses found that children 6-12 years of age did not have a significantly different BMI z-score (z = 1.76; P = 0.08) and body weight (z = 1.75; P = 0.08) versus adolescents.
    3 context sentences
    Summary · context
    Liraglutide significantly decreased body mass index (BMI) (WMD: -0.57; P = 0.007)
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.
  9. 09HumanSystematic reviewEfficacy outcome

    Fifty-six weeks of liraglutide significantly reduced body mass index z-score versus short-term treatment of less than 13 weeks.

    In plain wordsIn children and adolescents with obesity, fifty-six weeks of liraglutide lowered body mass index z-score more than treatment under 13 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index z-score after 56 weeks
    Study

    n: not reported in source

    Comparator
    Short-term treatment group (<13 weeks)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    Fifty-six weeks of liraglutide treatment (z = 4.60; P < 0.00001) significantly reduced the BMI z-score versus the short-term treatment group (<13 weeks) (z = 1.20; P = 0.23).
    2 context sentences
    Summary · context
    compared with placebos in obese children and adolescents.
    Summary · context
    Randomized controlled trials published up to March 20, 2025 were retrieved from in PubMed, Embase, Scopus, Cochrane library, Web of Science, and Google Scholar.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.